Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.
Nephrol Dial Transplant. 2012 Apr;27(4):1613-8. doi: 10.1093/ndt/gfr497. Epub 2011 Sep 2.
Individuals with end-stage kidney disease appear to have stable pre-dialysis serum sodium concentrations over time, with lower values associating with increased mortality. Dialysate sodium concentrations have increased over many years in response to shorter treatments, but the relationship between serum sodium, dialysate sodium and outcomes in chronic hemodialysis patients has not yet been systematically examined.
We studied a cohort of 2272 individuals receiving thrice-weekly hemodialysis treatment. Available data included demographics, laboratory and clinical measures, details of the dialysis prescription and 30-month follow-up. We examined the distribution of serum and dialysate sodium among subjects and compared mortality according to dialysate and serum sodium concentrations using Cox regression models.
Dialysate sodium concentration varied within and among dialysis centers. The pre-dialysis serum sodium concentration (mean 136.1 mmol/L) did not differ across dialysate sodium concentrations. There was evidence for effect modification for mortality according to differing serum sodium and dialysate sodium concentrations (P=0.05). For each 4 mmol/L increment in serum sodium, the hazard ratio for death was 0.72 [95% confidence interval (CI) 0.63-0.81] with lower dialysate sodium compared to 0.86 (95% CI 0.75-0.99) for higher dialysate sodium. Higher dialysate sodium concentration was associated with mortality at higher, but not lower, pre-dialysis serum sodium concentrations.
The pre-dialysis serum sodium concentration appears to be unaffected by the dialysate sodium concentration. The relationship between serum and dialysate sodium and mortality appears to be variable. Further research is warranted to determine the biological mechanisms of these associations and to re-examine total body sodium handling in hemodialysis.
终末期肾病患者的血清钠浓度似乎随时间保持稳定,低值与死亡率增加相关。多年来,由于治疗时间缩短,透析液钠浓度不断升高,但血清钠、透析液钠与慢性血液透析患者结局之间的关系尚未得到系统研究。
我们研究了一个接受每周三次血液透析治疗的 2272 人的队列。可用数据包括人口统计学、实验室和临床指标、透析处方细节和 30 个月的随访。我们检查了研究对象的血清和透析液钠分布,并使用 Cox 回归模型比较了根据透析液和血清钠浓度的死亡率。
透析液钠浓度在个体和透析中心内均存在差异。透析前血清钠浓度(平均值 136.1mmol/L)在不同透析液钠浓度之间没有差异。根据不同的血清钠和透析液钠浓度,死亡率存在显著的交互作用(P=0.05)。与低透析液钠浓度相比,血清钠每增加 4mmol/L,死亡的风险比为 0.72(95%置信区间 0.63-0.81),而高透析液钠浓度的风险比为 0.86(95%置信区间 0.75-0.99)。高透析液钠浓度与较高而非较低的透析前血清钠浓度相关死亡率。
透析前血清钠浓度似乎不受透析液钠浓度的影响。血清和透析液钠与死亡率之间的关系似乎是可变的。需要进一步研究以确定这些关联的生物学机制,并重新检查血液透析中的总体钠处理。